No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
TEVA240726P15500
- 0.03
- -0.04-57.14%
15min DelayTrading Jul 22 10:09 ET
0.03High0.03Low
0.03Open0.07Pre Close1 Volume219 Open Interest15.50Strike Price3.00Turnover55.92%IV9.48%PremiumJul 26, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type-0.0540Delta0.1025Gamma683.60Leverage Ratio-0.0115Theta-0.0001Rho-36.89Eff Leverage0.0021Vega
Intraday
- 5D
- Daily
News
Hims & Hers Appoints Former Novo Nordisk President to Board
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
Teva Pharmaceutical Indus (NYSE:TEVA) has outperformed the market over the past 5 years by 4.1% on an annualized basis producing an average annual return of 16.96%. Currently, Teva Pharmaceutical
TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids
Teva's Migraine Treatment Found Effective For Children As Young As 6
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) announced on Thursday topline results from its Phase 3 SPACE study evaluating the efficacy of Ajovy (fremanezumab) for the prevention of episodic
Teva Pharmaceutical Says Trial of Ajovy to Prevent Episodic Migraine in Children Reaches Primary Endpoint
Teva Pharmaceutical Industries (TEVA) said Thursday its phase 3 trial assessing Ajovy's effectiveness in preventing episodic migraine in children and adolescents reached its primary endpoint.The
Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY (Fremanezumab) SPACE Trial for Prevention of Episodic Migraine
SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to placeboEfficacy is consistent with AJOVY (fremanezumab)
Comments
$Fortinet(FTNT.US$ : “I think Fortinet is not my favorite. Palo Alto is, we own it for the Charitable Trust.”
$Air Products & Chemicals(APD.US$ : “You really don’t want to be in Air Products, you want to be in Linde. Linde’s a much better run company, and that’s why Air Products isn’t doing as well , and Linde’s doing spectacularly.”
$Sarepta Therapeutics(SRPT.US$ : “I think Sarepta is a speculative situation where they have great science. ...
$Air Products & Chemicals(APD.US$ : “You really don’t want to be in Air Products, you want to be in Linde. Linde’s a much better run company, and that’s why Air Products isn’t doing as well , and Linde’s doing spectacularly.”
$Sarepta Therapeutics(SRPT.US$ : “I think Sarepta is a speculative situation where they have great science. ...
1
1
$Teva Pharmaceutical Industries(TEVA.US$ better than anticipated revenue growth 📈
MAYDAY!!!
🤣 hahaha, my favorite gif 🤣
🎵 Here's where the story ends
It's that little souvenir of a terrible year
Which makes my eyes feel sore
It's that little souvenir of a terrible year
Surprise, surprise, surprise 🎵
I'm going to try and get a post out. I'm really uncomfortable and sore, but there are some big moves and big news ahead.
A little Sundays to start the day
As I said, I'm fresh out of the hospital again. I've been oversleeping and much too tired 😫. I feel gu...
🤣 hahaha, my favorite gif 🤣
🎵 Here's where the story ends
It's that little souvenir of a terrible year
Which makes my eyes feel sore
It's that little souvenir of a terrible year
Surprise, surprise, surprise 🎵
I'm going to try and get a post out. I'm really uncomfortable and sore, but there are some big moves and big news ahead.
A little Sundays to start the day
As I said, I'm fresh out of the hospital again. I've been oversleeping and much too tired 😫. I feel gu...
loading...
21
4
its not bad if you hold it. it's just not my thing. too many swaps and derivatives for my liking.
$Teva Pharmaceutical Industries(TEVA.US$ & alvotechpr
📣 FDA approves SELARSDI (Ustekinumab-Aekn), biosimilar to Stelara® 🎉
▻ approved for both adult and pedia indications (plaque psoriasis & psoriatic arthritis)
▻ developed and manuf. using same type of cells and process used for Stelara 👨🔬
▻ to be marketed in US on or after 02/21/25 🗓️
📣 FDA approves SELARSDI (Ustekinumab-Aekn), biosimilar to Stelara® 🎉
▻ approved for both adult and pedia indications (plaque psoriasis & psoriatic arthritis)
▻ developed and manuf. using same type of cells and process used for Stelara 👨🔬
▻ to be marketed in US on or after 02/21/25 🗓️
3
1
Read more
LELT : In practice co diversity the security risk. This preclude Fortinet and Fortinet has solid FS